Sarepta Therapeutics Inc (SRPT) Shares Sold by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. decreased its stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 8.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 303,006 shares of the biotechnology company’s stock after selling 28,635 shares during the quarter. Pinnacle Associates Ltd.’s holdings in Sarepta Therapeutics were worth $16,859,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in SRPT. Ameriprise Financial Inc. lifted its position in Sarepta Therapeutics by 25.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 42,489 shares of the biotechnology company’s stock worth $1,432,000 after buying an additional 8,581 shares in the last quarter. New York State Common Retirement Fund lifted its position in Sarepta Therapeutics by 4.9% in the 2nd quarter. New York State Common Retirement Fund now owns 55,500 shares of the biotechnology company’s stock worth $1,871,000 after buying an additional 2,599 shares in the last quarter. Northern Trust Corp lifted its position in Sarepta Therapeutics by 3.4% in the 2nd quarter. Northern Trust Corp now owns 629,504 shares of the biotechnology company’s stock worth $21,221,000 after buying an additional 20,680 shares in the last quarter. Parametric Portfolio Associates LLC lifted its position in Sarepta Therapeutics by 0.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 109,852 shares of the biotechnology company’s stock worth $3,703,000 after buying an additional 818 shares in the last quarter. Finally, Stifel Financial Corp lifted its position in Sarepta Therapeutics by 100.3% in the 2nd quarter. Stifel Financial Corp now owns 26,766 shares of the biotechnology company’s stock worth $901,000 after buying an additional 13,400 shares in the last quarter. Institutional investors own 86.62% of the company’s stock.

A number of equities research analysts have issued reports on the stock. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday. Zacks Investment Research downgraded shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. JPMorgan Chase & Co. restated an “overweight” rating and set a $75.00 price target (up previously from $63.00) on shares of Sarepta Therapeutics in a report on Wednesday. UBS Group restated an “outperform” rating and set a $56.51 price target (down previously from $76.00) on shares of Sarepta Therapeutics in a report on Wednesday, December 27th. Finally, HC Wainwright set a $75.00 price target on shares of Sarepta Therapeutics and gave the company a “buy” rating in a report on Monday, February 12th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nineteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $66.15.

In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the transaction, the director now owns 13,333 shares in the company, valued at approximately $745,181.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 9.60% of the company’s stock.

Sarepta Therapeutics Inc (NASDAQ:SRPT) opened at $63.22 on Thursday. The company has a market cap of $4,063.41, a price-to-earnings ratio of -30.84 and a beta of 1.49. Sarepta Therapeutics Inc has a twelve month low of $28.14 and a twelve month high of $68.90. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04.

TRADEMARK VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/22/sarepta-therapeutics-inc-srpt-shares-sold-by-pinnacle-associates-ltd.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply